Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in Patients with HR-positive/HER2-negative, PIK3CA Wild-Type ABC By Ogkologos - March 17, 2026 6 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VIKTORIA-1 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment in Patients with MIBC and Response Can Be Monitored by ctDNA MOST POPULAR No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... November 17, 2025 Immunotherapy Drug with Two Targets Shows Promise against HPV-Related Cancers April 25, 2019 Improving research with registered reports May 16, 2022 American tobacco company Philip Morris International offers £1bn for UK pharma... July 9, 2021 Load more HOT NEWS Visits to Online Breast Cancer Communities Could Help Policy Makers and... Cancer Research UK spin-out goes public, ready to invest more in... Prostate cancer: Lessons Learned from My Breast Cancer Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with...
